8-K: Accuray Reports Mixed Q3 Results, Adjusts Full-Year Guidance Amidst US Market Slowdown

Accuray's third quarter results show a revenue decrease and a net loss, despite a significant increase in gross orders, leading to a revised full-year financial outlook.

Summary

• Accuray reported a 14% decrease in net revenue for the third quarter of fiscal year 2024, totaling $101.1 million, compared to $118.1 million in the same period last year.
• The company experienced a GAAP net loss of $6.3 million in Q3, a downturn from the $0.6 million net income in the prior year's third quarter.
• Adjusted EBITDA for the quarter was $1.1 million, significantly lower than the $8.3 million reported in the same quarter of the previous year.
• Despite the revenue and profit challenges, gross orders increased by 21% year-over-year, reaching $89.1 million, and the book-to-bill ratio improved to 1.8.
• For the first nine months of fiscal year 2024, net revenue decreased by 5% to $312.3 million, and the GAAP net loss was $18.9 million, compared to a $6.7 million loss in the same period last year.
• Accuray has adjusted its full-year fiscal 2024 guidance, now expecting total revenue between $432 million and $437 million, and adjusted EBITDA between $19 million and $22 million.
• The company attributes the adjusted guidance to a slowdown in the US market and further deterioration of the Yen.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with strong order growth offset by significant revenue and profit declines, leading to a revised full-year outlook. The negative financial results and lowered guidance outweigh the positive order growth and new initiatives, resulting in a negative sentiment.

Positives

• Gross orders increased by 21% year-over-year in Q3, indicating strong customer demand.
• The book-to-bill ratio improved to 1.8 in Q3, up from 1.2 in the same period last year.
• Accuray opened a new training center in Switzerland, which is expected to drive service business growth.
• The company is introducing innovative solutions like CyberComm to improve system efficiency.
• A new collaboration with Oncopole and Airbus aims to develop AI-driven solutions for radiotherapy system performance.

Negatives

• Net revenue decreased by 14% in Q3 compared to the same period last year.
• The company experienced a net loss of $6.3 million in Q3, a significant drop from the net income of $0.6 million in the prior year's Q3.
• Adjusted EBITDA decreased significantly to $1.1 million in Q3, compared to $8.3 million in the same period last year.
• Accuray has lowered its full-year revenue and adjusted EBITDA guidance due to a slowdown in the US market and currency fluctuations.
• Cash, cash equivalents, and short-term restricted cash decreased by $28.8 million from June 30, 2023 to $61.1 million as of March 31, 2024.

Risks

• The company faces risks related to the global macroeconomic environment, which could impact operations and customer demand.
• Supply chain disruptions and increased logistics costs could negatively affect the company's ability to deliver products.
• There is a risk that the company may not achieve widespread market acceptance of its products, including new offerings.
• Delays in regulatory approvals or the development of new products could impact the company's growth.
• The company's ability to meet the covenants under its credit facilities is a potential risk.
• The company is facing headwinds in the US market due to longer capital equipment cycles.
• Currency fluctuations, particularly the deterioration of the Yen, are impacting financial results.

Future Outlook

Accuray has adjusted its full-year fiscal 2024 guidance, now expecting total revenue between $432 million and $437 million, and adjusted EBITDA between $19 million and $22 million. The company is focused on executing its strategic growth plan, advancing care with innovative solutions, improving patient access, and investing in its service business.

Management Comments

• Suzanne Winter, Chief Executive Officer, stated that while she is disappointed in the quarterly results due to multiple factors, including a delay in product shipments and slower than expected U.S. installations, she remains confident in the company's growth strategy.
• She also noted that fiscal 2024 is an important year for the company as they start to make major advances in long-term growth and profitability drivers.
• She expressed pleasure with customer adoption of their solutions this quarter, which led to a 21% increase in gross orders year-over-year.

Industry Context

Accuray's results reflect challenges in the medical device industry, including supply chain issues, macroeconomic pressures, and longer capital equipment cycles. The company's focus on innovation and expanding its service business aligns with industry trends towards value-added solutions and recurring revenue streams. The collaboration with Airbus and Oncopole highlights the growing importance of AI in healthcare.

Comparison to Industry Standards

• Accuray's revenue decline contrasts with some competitors in the medical device space who have shown growth, such as Varian Medical Systems (now part of Siemens Healthineers) which has seen growth in its oncology segment.
• The 21% increase in gross orders is a positive sign, but the company needs to convert these orders into revenue more effectively, which is a challenge also faced by other companies in the capital equipment sector.
• The adjusted EBITDA margin of 1.1% in Q3 is significantly lower than industry benchmarks, where companies like Elekta often report higher margins.
• Accuray's book-to-bill ratio of 1.8 is a positive indicator of future revenue potential, but it needs to be sustained and translated into actual sales.
• The company's investment in training centers is a strategy similar to other medical device companies that focus on customer support and education to drive adoption and service revenue.

Stakeholder Impact

• Shareholders will be negatively impacted by the decreased revenue, net loss, and lowered guidance.
• Employees may be affected by the company's restructuring efforts and cost-saving measures.
• Customers may experience delays in product shipments and installations.
• Suppliers may be affected by changes in the company's production and purchasing plans.
• Creditors may be concerned about the company's financial performance and ability to meet its obligations.

Next Steps

• Accuray will continue to execute its strategic growth plan.
• The company will focus on advancing care with innovative solutions.
• Accuray will work to improve patient access by penetrating higher growth emerging markets.
• The company will continue to invest in its service business.
• Accuray will host a conference call to discuss the results and recent developments.

Key Dates

Keywords

Accuray, Radiotherapy, CyberKnife, TomoTherapy, EBITDA, Revenue, Medical Devices, Healthcare, Oncology, Gross Orders, Book to Bill Ratio